Molecular vaccines against animal parasites

Murray, P.K.

doi:10.1016/0264-410x(89)90188-6

Cited by 14 publications

(15 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our results indicate that immunization with a recombinant schistosome-derived molecule can prevent, in a high percentage of animals, the establishment of heavy worm burdens and can reverse growth impairment in experimentally infected goats. As usually observed with molecular vaccines (Murray 1989), the immunity was not sterilizing. Likewise, variations in the levels of protection compared to the controls were noticeable; similar variability had already been recorded in the context of purified molecules against parasitic diseases in other outbred models like Aotus monkeys immunized against Plasmodium (Inselburg et al 1993), cattle immunized against Boophilus (Johnston et al 1986) or, closer to our model, baboons immunized against S. mansoni.…”

Section: Discussionmentioning

confidence: 69%

“…1992, MacMahon-Pratt et al 1993 or schistosomes (Pierce et al 1990). The overall strategy has been to replace an existing live vaccine, difficult to produce and unacceptable for human use, by a defined protective antigen, safer and more suitable for large-scale application (Murray 1989). However, in the field of veterinary research, cloned antigens have been more frequently used for immunodiagnosis (Schnieder et al 1992) than for their protective activity.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Vaccination of goats against the trematode Schistosoma bovis with a recombinant homologous schistosome‐derived glutathione S‐transferase

Boulanger

Trottein

Mauny

et al. 1994

Parasite Immunology

View full text Add to dashboard Cite

We assayed the vaccine potentialities of a recombinant S. bovis-derived glutathione S-transferase (rSb28GST), member of a molecular family already shown to have protective capacities in the S. mansoni and S. japonicum models. Injection of the rSb28GST in Freund's Complete Adjuvant resulted in good specific IgG responses allowing all the animals to display high antibody titres on the day of experimental challenge with S. bovis cercariae. No statistically significant differences were observed in the faecal egg output. Although tissue egg counts in vaccinated animals were lower than in controls, the difference was not statistically significant, apart from the number of eggs trapped in the liver (P < 0.05). Likewise, PCV values remained parallel between the two groups. However, immunized goats gained 1.4 kg of body weight throughout the experiment whereas controls lost 1.2 kg (P < 0.05). In addition, the mean worm burden, assessed by perfusion 20 weeks after infection, was significantly reduced by 48% in the vaccinated group, the sex ratio being unaffected. It appears that a recombinant homologous protein can affect, in a natural host, the course of an experimental infection with a local strain of S. bovis, by affecting worm viability but not fecundity. These results also point to the striking differences in the effect of vaccination according to animal species. Because it has the capacity to prevent growth impairment due to schistosome pathogenicity, the molecule can be proposed as a valuable tool in the development of vaccine-based control programs in endemic areas.

show abstract

Section: Discussionmentioning

confidence: 69%

Section: Discussionmentioning

confidence: 99%

Vaccination of goats against the trematode Schistosoma bovis with a recombinant homologous schistosome‐derived glutathione S‐transferase

Boulanger

Trottein

Mauny

et al. 1994

Parasite Immunology

View full text Add to dashboard Cite

show abstract

“…In the field of schistosomiasis mansoni, efforts have been focused, for the last decade, on the elaboration of a reliable vaccine able to protect man against natural infection. Although attenuated larvae can induce a good level of immunity in various experimental models (Taylor & Bickle 1986), it is commonly agreed that a non living, defined vaccine would be easier to produce on a large scale, by recombinant DNA technology, as well as being ethically more acceptable in human populations (Murray 1989). The production of a recombinant protein, namely Sm28GST, a member of the glutathione S-transferase family (Taylor, J.B. et al 1988), capable of protecting rodents at a high level against challenge with Schistosoma munsoni (Balloul et al 1987b), incited us to assay the efficacy of Sm28GST in a primate model.…”

Section: Introductionmentioning

confidence: 99%

Immunization of mice and baboons with the recombinant Sm28GST affects both worm viability and fecundity after experimental infection with Schistosoma mansoni

Boulanger

Reid

Sturrock

et al. 1991

Parasite Immunology

160

View full text Add to dashboard Cite

A member of the glutathione S-transferase family, Sm28GST has previously demonstrated a good ability to protect rodents against experimental infection with Schistosoma mansoni. In order to evaluate its efficacy in a model closer to man, two different protocols of immunization with recombinant Sm28GST were tested on baboons in a large-scale trial. Three injections in the presence of aluminium hydroxide as adjuvant resulted in a significant 38% reduction in the adult worm burden together with a trend for a lower percentage of inflammatory tissue in the liver. Individual levels of protection, ranging from 0 to 80%, underlined the heterogeneity of the immune response to this purified molecule in outbred primates. On the other hand, two injections of Sm28GST in the presence of aluminium hydroxide and Bordetella pertussis reduced female schistosome fecundity by 33%, with a more pronounced effect (66%) on faecal egg output; there was also a trend, in this protocol, for decrease of the mean granuloma surface in the liver. Individual anti-Sm28GST IgG antibodies were apparently unrelated to levels of immunity, but there was partial evidence that cytophilic IgE might play a role in the immune mechanisms affecting worm viability, but not fecundity. In the mouse model, Sm28GST vaccination resulted in a lower hatching ability of tissue eggs recovered from immunized mice whereas passive transfer of specific anti-Sm28GST T-lymphocytes, one day before infection, significantly reduced the number of eggs in the liver of mice. We propose that different protocols of immunization with a recombinant molecule can impede Schistosoma mansoni worm viability and fecundity, but can also affect miracidium physiology, with important consequences for disease transmission and granuloma-derived pathology.

show abstract

“…The formulation also includes MDP (muramyl di-peptide) which is an excellent stimulator of T-cell response (8). Finally, there is the possibility of producing recombinant viruses or bacteria that can be given directly to the host to form the protective antigen in situ (51). Each of these strategies will undoubtedly prove to have disadvantages as well as advantages in practice and the exciting potential for any of these approaches for use against GI nematodes obviously has yet to be fully explored.…”

Section: Presentation Of Immunogen To Immune Systemmentioning

confidence: 99%

Strategies for vaccination against gastro-intestinal nematodes

Smith¹,

Munn²

1990

Rev. Sci. Tech. OIE

View full text Add to dashboard Cite

A great diversity of gastro-intestinal nematodes parasitise man and his animals. Each nematode is antigenically highly complex with distinct developmental stages. The parasites occupy a range of niches in the host gut and have a variety of feeding habits. Hosts have evolved only partially successful local immune responses. The host and parasite factors modulating these responses are described.Strategies for vaccination are surveyed. It is argued that the best route to successful vaccines will be to seek parasite immunogens which are not normally seen by the host's immune system in the course of infection. Routes to be followed in identifying and characterising such immunogens are proposed and methods for evaluating and maximising the immune response are surveyed. The success of this strategy is illustrated by reference to an experimental molecular vaccine against Haemonchus contortus. Strategies for the use of vaccines and methods for their production in vitro are reviewed.

show abstract

Molecular vaccines against animal parasites

Cited by 14 publications

References 55 publications

Vaccination of goats against the trematode Schistosoma bovis with a recombinant homologous schistosome‐derived glutathione S‐transferase

Vaccination of goats against the trematode Schistosoma bovis with a recombinant homologous schistosome‐derived glutathione S‐transferase

Immunization of mice and baboons with the recombinant Sm28GST affects both worm viability and fecundity after experimental infection with Schistosoma mansoni

Strategies for vaccination against gastro-intestinal nematodes

Contact Info

Product

Resources

About